miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype
- PMID: 23606360
- DOI: 10.1002/jcb.24574
miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype
Abstract
Resistance to chemotherapy is a major obstacle for the effective treatment of breast cancer and is partially due to the presence of drug resistant stem cell-like side population (SP). Previous studies have shown elevated miR-125b is associated with chemoresistance and metastasis; however, the relationship between miR-125b and SP cells remains unknown. In this study, we isolated and characterized SP cells in a panel of breast cancer cell lines and primary cancer cells from breast cancer patients. SP cells showed cancer stem cells (CSCs) properties, including self-renewal, resistance to chemotherapy and high expression of stem cell markers. The percentage of SP cells was higher in chemotherapy resistant patients compared to that in chemotherapy responsive patients (5.8 ± 2.4% in non-responsive patients vs. 1.2 ± 0.5% in responsive patients, P = 0.012). Importantly, SP cells had higher level of miR-125b than NSP cells and the elevated miR-125b expression in chemoresistant cancer cells were due to high percentage of SP cells. Overexpression of miR-125b correlated with an increase in tumor SP and CSC property, whereas knockdown of miR-125b correlated with decreased incidence of SP. In addition, miR-125b overexpression in breast cancer cells induced epithelial-mesenchymal transition (EMT)-like cellular marker alteration, suggesting a potential mechanism of miR-125b in the regulation of cancer stem-like SP cells. Taken together, these results suggest an important role for miR-125b in breast cancer chemoresistance by maintaining cancer stem-like SP fraction, and raise the possibility that miR-125b may be a significant prognostic response marker for cancer therapy.
Keywords: BREAST CANCER; CANCER STEM CELLS; CHEMORESISTANCE; SIDE POPULATION; miR-125B.
Copyright © 2013 Wiley Periodicals, Inc.
Similar articles
-
MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.Oncotarget. 2015 Feb 20;6(5):3268-79. doi: 10.18632/oncotarget.3065. Oncotarget. 2015. PMID: 25605244 Free PMC article.
-
MiR-888 regulates side population properties and cancer metastasis in breast cancer cells.Biochem Biophys Res Commun. 2014 Aug 8;450(4):1234-40. doi: 10.1016/j.bbrc.2014.05.022. Epub 2014 May 15. Biochem Biophys Res Commun. 2014. PMID: 24845571
-
MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.Hepatology. 2015 Sep;62(3):801-15. doi: 10.1002/hep.27887. Epub 2015 Jul 3. Hepatology. 2015. PMID: 25953743
-
The Role of MicroRNAs in the Chemoresistance of Breast Cancer.Drug Dev Res. 2015 Nov;76(7):368-74. doi: 10.1002/ddr.21275. Epub 2015 Aug 27. Drug Dev Res. 2015. PMID: 26310899 Review.
-
Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells.Future Oncol. 2015;11(6):983-95. doi: 10.2217/fon.14.301. Future Oncol. 2015. PMID: 25760978 Review.
Cited by
-
miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.Breast Cancer Res. 2017 Dec 19;19(1):133. doi: 10.1186/s13058-017-0918-2. Breast Cancer Res. 2017. PMID: 29258605 Free PMC article.
-
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature.Cancers (Basel). 2021 Sep 29;13(19):4894. doi: 10.3390/cancers13194894. Cancers (Basel). 2021. PMID: 34638377 Free PMC article.
-
The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers.Cell Oncol (Dordr). 2015 Dec;38(6):443-51. doi: 10.1007/s13402-015-0240-x. Epub 2015 Sep 3. Cell Oncol (Dordr). 2015. PMID: 26335100
-
MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.Oncotarget. 2015 Feb 20;6(5):3268-79. doi: 10.18632/oncotarget.3065. Oncotarget. 2015. PMID: 25605244 Free PMC article.
-
miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism.Drug Des Devel Ther. 2016 Feb 24;10:571-83. doi: 10.2147/DDDT.S90530. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26966351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical